CG Oncology Q2 net loss widens on higher R&D costs
CG Oncology Q2 net loss widens on higher R&D costs
Overview
US biopharmaceutical firm's Q2 rev rose to $1.2 mln, reflecting early commercialization activity
Net loss widened to $79.1 mln, driven by higher R&D and G&A expenses
Company ended Q2 with $1.0 bln cash, sufficient to fund operations through 2029
Outlook
CG Oncology expects PIVOT-006 Phase 3 topline data in the near-term
Company anticipates BLA completion for HR BCG-unresponsive NMIBC in 4Q'26
CG Oncology says cash position sufficient to fund operations through 2029
Result Drivers
CLINICAL TRIAL EXPENSES - Co said higher R&D expenses were primarily due to increased clinical trial activity and CMC costs
COMPENSATION COSTS - Co attributed increased R&D and G&A expenses to higher compensation costs from increased headcount
Company press release: ID:nGNX8GDqKV
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Loss Per Share |
| $0.90 |
|
Q2 Net Loss |
| $79.10 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for CG Oncology, Inc. is $88.50, about 22.2% above its August 5 closing price of $72.42
Reuters Recommended Reads
Aug 5 - Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates
Aug 6 - Compass Therapeutics Q2 net loss widens on higher R&D and G&A costs
Aug 6 - Avalo Therapeutics Q2 net loss widens, driven by higher R&D expenses
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)